Wanbury Initiates Commercial Production of Anaesthetic API at Tanuku
Filing Summary
Wanbury Ltd has commenced commercial production of a key anaesthetic Active Pharmaceutical Ingredient (API) at its Tanuku facility in Andhra Pradesh. This development is projected to contribute incremental revenue of approximately Rs. 100 crore in FY 2026-27. The facility is also set to produce additional high-value APIs, including Antidiabetic and Anticoagulant products. The company aims to achieve commercial readiness by March 2026. Wanbury’s strategic expansion aligns with its focus on meeting global healthcare demands through reliable API supply.
Wanbury Ltd has announced the commencement of commercial production for a key anaesthetic Active Pharmaceutical Ingredient (API) at its facility located in Tanuku, Andhra Pradesh. This initiative is part of the company’s strategy to enhance its presence in the domestic and global API markets. The production is expected to generate incremental revenue of approximately Rs. 100 crore in the financial year 2026-27.
The Tanuku facility’s production of the anaesthetic API is anticipated to contribute significantly to Wanbury’s revenue growth. The company has projected incremental revenues of approximately Rs. 18 crore in the fourth quarter of FY 2025-26. The facility is also set to produce additional high-value APIs, including Antidiabetic, Anticoagulant, and Antidepressant products. Together, these products are expected to deliver substantial revenue for Wanbury in FY 2026-27.
The scope of the Tanuku facility includes the production of four additional high-value APIs: Antidiabetic, Anticoagulant, Cough Suppressant, and Antidepressant. These products are projected to deliver over Rs. 100 crore in revenue, driven by strong global demand. The facility’s versatile production block is on track for commercial readiness by the end of March 2026, enabling the company to meet robust supply requirements.
Wanbury’s expansion into the production of high-potency anaesthetic APIs aligns with its strategic focus on capturing a larger share of the global API market. The company has a strong presence in both domestic and international markets, exporting to over 50 countries. Its facilities in Tanuku and Patalganga are USFDA and EUGMP approved, ensuring compliance with international quality standards.
The timeline for the Tanuku facility’s commercial readiness is set for the end of March 2026. This timeline includes the production of the anaesthetic API and additional high-value APIs. The facility’s strategic location in Andhra Pradesh supports Wanbury’s goal of enhancing its production capabilities and meeting global healthcare needs.
Wanbury Ltd, established in 1988, is a leading pharmaceutical company with a strong presence in the API and branded formulations markets. The company focuses on expanding its API portfolio and meeting global healthcare demands with reliable, high-quality supply. Wanbury’s strategic initiatives include enhancing its production capabilities and expanding its market reach to over 50 countries.